Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LB PHARMACEUTICALS INC (LBRX)

LB Pharmaceuticals appoints Susan Kozauer, M.D. as Chief Medical Officer

Neutral Impact 3 of 5 leadership Written later

LB Pharmaceuticals named Susan G. Kozauer, M.D. as its Chief Medical Officer, effective September 14, 2026, with a $515,000 base salary and an option to buy 200,000 shares. The company says she will lead clinical development of LB-102 ahead of Phase 3 NOVA-2 topline results expected in the first half of 2027.

Key points

  • Effective start date: September 14, 2026; base salary $515,000 with a 40% target bonus
  • One-time sign-on bonus of $150,000, with a 200,000-share option subject to four-year vesting
  • Severance: nine months of base salary and COBRA for up to nine months; enhanced terms apply within the change-of-control window
  • CEO Heather Turner said Phase 3 NOVA-2 topline results are expected in the first half of 2027

The filing

CompanyLB PHARMACEUTICALS INC (LBRX)
Form8-K, current report
Filed with the SECSep 15, 2026, 8:05 AM ET
Accession number0001193125-26-391358

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.